IARC Maps Uneven Prostate Cancer Capacity Across EU
- PRAISE-U pilots analysed for screening readiness
- MRI shortages identified as a key bottleneck
- Workforce capacity varies significantly across regions
- IARC report sets baseline for EU cancer policy
- Prostate cancer screening remains uneven in Europe
European health systems face a steep uphill battle to implement uniform prostate cancer screening, according to a major new analysis released today by the International Agency for Research on Cancer (IARC). The report, titled 'Mapping the readiness landscape for prostate cancer screening in Europe', provides a granular examination of health system capacity across the PRAISE-U pilot sites. Officials at the Lyon-based agency said the findings reveal a fragmented landscape where infrastructure and workforce shortages threaten the success of upcoming early detection programmes. Prostate cancer remains the second most common cancer among men in Europe, causing hundreds of thousands of deaths annually, yet the ability to diagnose it early varies wildly from one region to the next. The IARC assessment serves as a reality check for policymakers, moving beyond theoretical screening guidelines to the practical realities of what hospitals and clinics can actually handle.
The context for this report is the European Council's recommendation from late 2023, which urged member states to adopt organised, population-based screening for prostate cancer using prostate-specific antigen (PSA) testing as an initial touchpoint. However, the IARC data suggests that the infrastructure required to support a positive PSA test is dangerously uneven. While PSA testing itself is relatively simple and cheap, the diagnostic cascade it triggers—ranging from MRI scans to targeted biopsies and histopathological confirmation—is resource-intensive. The analysis warns that without a robust downstream capacity, a surge in screening invitations could lead to a 'bottleneck effect,' where men are left in diagnostic limbo, experiencing profound anxiety while waiting for essential follow-up procedures.
The disparity in readiness is not merely a matter of national wealth but of strategic planning. The report notes that some countries with high GDP per capita still suffer from fragmented care pathways where primary care physicians, radiologists, and urologists operate in silos. This lack of integration creates administrative friction that slows down patient journeys. Conversely, some less wealthy regions have achieved higher readiness scores by centralising services and creating streamlined referral networks. The IARC assessment effectively creates a scoreboard of readiness, highlighting which nations are prepared to roll out population-based screening and which are lagging behind due to a lack of essential resources. This mapping is not just an academic exercise; it is a necessary precursor to any mass screening invitation, ensuring that when a man receives a test, the system is robust enough to follow through on the results.
"We cannot simply invite men for screening if the health system lacks the capacity to manage the subsequent diagnostic pathway," a senior IARC researcher involved in the study said. The report underscores that readiness is a multifaceted concept, encompassing not just the availability of MRI machines but also the specialised radiologists needed to interpret them and the pathologists to confirm diagnoses. As EU member states review their national cancer control plans, this data provides the evidence base needed to direct funding where it is needed most, potentially reshaping the continent's approach to men's health in the coming decade. The findings will be pivotal for the European Commission's implementation of the 'Europe's Beating Cancer Plan,' particularly regarding the specific budget lines allocated to supporting member states in upgrading their diagnostic infrastructure.
PRAISE-U Pilots Reveal Stark Infrastructure Disparities
The PRAISE-U project, which stands for Prostate Cancer Awareness and Screening Initiative in the European Union, was designed to test the feasibility of organised screening across different member states. However, the IARC's mapping of these pilot sites shows that the starting line is far from level for everyone involved. In several Northern and Western European pilot regions, the analysis found a relatively high density of diagnostic equipment and integrated care pathways, suggesting these areas are primed for immediate scale-up. In contrast, pilot sites in Eastern and Southern Europe reported significant gaps in hardware, specifically regarding the availability of high-resolution MRI scanners, which have become the gold standard for non-invasive prostate imaging.
This disparity means that a man in a well-resourced capital city might access a scan within weeks, whereas a man in a rural region of a lower-capacity country could face months of delay or be forced to travel abroad for diagnostics. The report details how the lack of physical infrastructure is often compounded by logistical inefficiencies, such as poor data sharing between general practitioners and specialists. In some sites, the referral process remains largely paper-based, slowing down the urgent tracking required for potential cancer cases. Infrastructure readiness also extends to the IT systems necessary to call men for screening, track their results, and monitor outcomes over time. Officials confirmed that several pilot sites are still operating with legacy software that cannot communicate with national cancer registries, creating a blind spot for public health officials trying to measure programme success.
These technical hurdles might seem mundane, but they are decisive in determining whether a screening programme functions smoothly or collapses under administrative weight. The IARC analysis suggests that standardising these IT platforms is just as important as buying new scanners. The report highlights specific instances where the lack of interoperability has led to 'lost patients'—individuals who screened positive but failed to appear for follow-up because the notification system failed. "The infrastructure gap is not merely about machines; it is about the entire ecosystem of care that supports the patient," the report states.
Furthermore, the analysis touches upon the role of the private sector. In many member states, a significant portion of MRI capacity is privately owned. While public-private partnerships can alleviate pressure, the report warns that relying on private capacity without clear contractual frameworks for screening programmes can lead to inequitable access. Patients with supplementary insurance or means to pay out-of-pocket may bypass queues, while those reliant solely on public systems face indefinite waits. Addressing these disparities will require targeted investment from both national governments and EU structural funds, as the market alone is unlikely to correct such geographical imbalances in the short term. The PRAISE-U pilots act as a stress test, exposing the weak points in the chain before a full-scale rollout potentially exacerbates existing inequalities in cancer survival.
The MRI Shortage: A Technical Barrier to Early Detection
A central theme emerging from the IARC mapping is the critical shortage of Magnetic Resonance Imaging (MRI) capacity, a factor that fundamentally limits the effectiveness of modern prostate cancer screening. Unlike traditional screening methods which relied heavily on PSA blood tests followed by invasive biopsies, contemporary best practice advocates for MRI as a triage tool to rule out cancer or pinpoint suspicious areas. This approach, often referred to as the 'MRI-first' pathway, significantly reduces the number of unnecessary biopsies and the associated complications, but it places a heavy burden on imaging departments.
The analysis found that in many PRAISE-U pilot regions, existing MRI machines are already operating at maximum capacity for neurological and orthopaedic scans, leaving little room for a sudden influx of prostate screening patients. Radiologists are the gatekeepers of this technology, and the report highlights a worrying shortage of these specialists, particularly in regions with ageing populations. Without enough trained staff to read the complex images, having the machine itself makes little difference. The IARC data suggests that some regions are relying on mobile MRI units or outsourcing scans to the private sector to cope with demand, but these are stop-gap solutions rather than sustainable long-term strategies.
Experts pointed out that the cost of expanding MRI capacity is high, running into millions of euros per scanner, but the economic cost of treating late-stage cancer is significantly higher. The analysis argues for a reallocation of resources, prioritising imaging capacity in diagnostic hubs that serve multiple screening catchment areas. Furthermore, the report notes that simply purchasing scanners is insufficient; they must be placed in settings where they are accessible to the target population and supported by maintenance contracts to prevent downtime. In some pilot sites, equipment downtime due to lack of spare parts or service engineers was cited as a major impediment to consistent screening services.
The technical barrier is therefore a compound issue of hardware, human resources, and supply chain resilience. The report also highlights the need for standardised MRI protocols across the EU. Currently, the quality of prostate MRI varies significantly, with some centres using outdated sequences that lack the sensitivity required for accurate screening (PI-RADS v2.1 standards). Without standardisation, a 'negative' scan in one region might not carry the same weight as one in a region with superior technology, leading to inconsistencies in patient care. "If we want to catch cancer early, we must be able to see it, and in many parts of Europe, we simply do not have enough eyes or enough equipment to do the job," a radiology consultant involved in the review noted. This finding is likely to influence how the EU allocates funding for health technology in the next budget cycle, shifting focus towards diagnostic infrastructure.
Workforce Shortages Strain Pathology and Urology Services
Beyond the machinery of diagnosis, the IARC report lays bare a chronic shortage of the human expertise required to confirm and treat prostate cancer. Pathologists, the doctors who analyse tissue samples to determine if cancer is present, are in particularly short supply across several of the analysed regions. This creates a severe bottleneck; even if a screening programme identifies a suspect case and an MRI locates a lesion, the system grinds to a halt if there is no one to analyse the biopsy. The report indicates that the time between taking a biopsy and receiving a histological result varies dramatically, ranging from a few days in best-performing centres to several weeks in under-resourced areas.
Urologists, who perform the biopsies and carry out surgeries or other treatments, are also stretched thin. In many regions, the ageing demographic of urologists mirrors the ageing patient population they serve, with a wave of retirements expected in the next five to ten years that is not being matched by a corresponding influx of medical graduates. The training pipeline for these specialists is long and arduous, meaning that funding increases today will not yield a fully trained workforce for at least another decade. This time lag presents a strategic challenge for EU health planners, who must balance the immediate political pressure to launch screening programmes with the long-term reality of workforce sustainability.
The report also sheds light on the shortage of specialist nurses and radiographers, who are essential for guiding patients through the screening and biopsy process. The lack of these support staff forces highly qualified doctors to spend time on administrative tasks rather than clinical care, further reducing system efficiency. Additionally, the analysis points to a maldistribution of expertise within countries. Major university hospitals often have sufficient staff, but regional hospitals and peripheral clinics—where the majority of the population might live—struggle to attract and retain specialists.
To mitigate this, the report suggests exploring cross-border collaboration models, where pathology samples or imaging data are sent to centres of excellence in neighboring countries or regions with surplus capacity. However, this requires robust legal frameworks and data sharing agreements that are currently lacking in many bilateral relationships. The findings suggest that without addressing the human capital crisis, any investment in physical infrastructure like scanners will fail to deliver the intended health outcomes. The report calls for emergency measures, including fast-tracking certification for foreign-trained specialists and incentivising specialisation in oncology fields through student loan forgiveness or targeted grants.
Economic Implications and the Cost of Inaction
The IARC report does not merely catalogue technical failures; it also delves into the profound economic implications of proceeding with screening without adequate capacity. The economic argument for early detection is predicated on the idea that treating stage I or II prostate cancer is significantly cheaper than managing stage IV metastatic disease. However, the report warns that if screening bottlenecks lead to delayed diagnoses despite positive tests, this economic advantage evaporates. Instead of saving money, health systems could face a 'double burden': the cost of running the screening programme plus the cost of treating more advanced cancers that were not caught early enough due to diagnostic delays.
Furthermore, the analysis highlights the hidden costs associated with the 'diagnostic odyssey' experienced by patients in under-resourced systems. Travel costs, lost productivity, and the psychological toll of prolonged uncertainty place a strain on individuals and the wider economy. In regions where patients must travel long distances for MRI or biopsy, the non-medical costs of care can become prohibitive, leading to dropout from the screening pathway. This inequity undermines the cost-effectiveness of population-based screening, which relies on high uptake rates across all socioeconomic groups to be viable.
The report also touches upon the opportunity cost of misallocated resources. Investing in mass screening invitations in regions that lack the capacity to follow up is essentially a waste of public funds that could be better spent on building infrastructure or training staff. The authors suggest a phased approach to implementation, where regions that meet a specific 'readiness threshold' are funded to launch screening immediately, while lagging regions receive 'capacity-building grants' to bring them up to standard over a defined period. This tiered approach, the report argues, would maximise the return on investment for the EU4Health programme and ensure that taxpayer money translates directly into saved lives rather than administrative backlogs.
Strategic Recommendations: Integrating AI and Centralised Care
Looking forward, the IARC analysis concludes with a set of strategic recommendations designed to bridge the capacity gap and ensure the successful rollout of the EU Beating Cancer Plan. A primary recommendation is the accelerated adoption of Artificial Intelligence (AI) in radiology and pathology. AI algorithms have shown promise in triaging MRI scans, flagging suspicious cases for urgent human review while automatically clearing negative cases. This could drastically reduce the workload on radiologists, effectively multiplying the existing workforce's capacity without requiring immediate hiring. Similarly, digital pathology tools can assist in the initial analysis of biopsy samples, allowing pathologists to focus on the most complex diagnoses.
Another key recommendation is the shift towards centralised 'hubs' for prostate cancer diagnostics. Rather than every small hospital attempting to maintain its own MRI scanner and pathology lab, the report advocates for the creation of regional diagnostic centres. These hubs would serve a network of smaller clinics, handling the complex imaging and analysis while the clinics manage the initial blood tests and patient follow-up. This model of care, already successfully implemented in some Scandinavian countries, optimises the utilisation of expensive equipment and concentrates scarce specialised expertise where it is needed most.
Finally, the report emphasises the need for robust data governance and the integration of screening data with broader cancer registries. By creating a unified digital ecosystem, health systems can monitor performance in real-time, identifying bottlenecks as they emerge and deploying resources dynamically. The success of PRAISE-U and the broader screening initiative will depend on the EU's ability to foster not just competition between member states, but deep, structural cooperation. The report serves as a blueprint for this cooperation, mapping out not just the deficits of the present, but the necessary architecture for a healthier future.